At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 13, 2026 at 16:00 ET
Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH) in hypoparathyroidism through 3.5 years (Week 182). 86% of patients met the multi-component endpoint, 89% completed the trial, and key renal, bone, and quality-of-life benefits were maintained with no new safety signals. This positive long-term data reinforces the drug's profile and supports continued commercial adoption, though the stock has historically underperformed following prior positive reports.
- 86% of patients were responders for the multi-component endpoint (normocalcemia, no active vitamin D, ≤600 mg/day calcium) at Week 182.
- 89% of patients completed the 3.5-year trial.
- 100% of patients achieved independence from active vitamin D; 96% from therapeutic calcium doses.
- Mean eGFR increased by 11.0 mL/min/1.73 m² from baseline and was maintained through Week 182, contrasting with expected age-related decline.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access